1
Richard Sackler, Robert Kaiko, Paul Goldenheim: Method of treating humans with opioid formulations having extended controlled release. Purdue Pharma, Davidson Davidson & Kappel, November 7, 2000: US06143322 (184 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rp ...


2
Mark Chasin, Benjamin Oshlack, Frank Pedi Jr: Opioid formulations having extended controlled release. Purdue Pharma, Davidson Davidson & Kappel, August 15, 2000: US06103261 (173 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rp ...


3
Sackler Richard, Oshlack Benjamin, Goldenheim Paul, Chasin Mark, Kaiko Robert, Pedi Frank: Opioid formulations having extended controlled release.. Euro Celtique, January 4, 1995: EP0631781-A1 (60 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rp ...


4
Richard Sackler, Robert Kaiko, Paul Goldenheim: Method of treating humans with opioid formulations having extended controlled release. Purdue Pharma, Davidson Davidson & Kappel, June 22, 2010: US07740881 (2 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method at 100 rp ...


5
Sackler Richard, Oshlack Benjamin, Goldenheim Paul, Chasin Mark, Kaiko Robert, Pedi Frank Jr: Opioid formulations having extended controlled release. Euro Celtique, September 25, 2002: EP1243269-A2 (2 worldwide citation)

Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rp ...


6
Sackler Richard, Oshlack Benjamin, Goldenheim Paul, Chasin Mark, Kaiko Robert, Pedi Frank Jr: Opioid formulations having extended controlled release. Euro Celtique, June 23, 2004: EP1430897-A2 (2 worldwide citation)

The use of a controlled release matrix material selected from the group consisting of hydrophilic and hydrophobic polymers, digestible long chain hydrocarbons and polyalkylene glycols in the manufacture of a solid oral dosage form comprising a therapeutically effective amount of an opioid analgesic ...


7
SACKLER RICHARD S, OSHLACK BENJAMIN, CHASIN MARK, GOLDENHEIM PAUL, KAIKO ROBERT, PEDI FRANK JR: [fr] Formulations dopioïdes à libération prolongée et contrôlée, [de] Opioidformulierungen mit verlängerter gesteuerter Wirkstoffabgabe, [en] Opioid formulations having extended controlled release. EURO CELTIQUE, December 22, 2010: EP2263673-A1

[en] A solid, controlled release, oral dosage form, the dosage form comprising an analgesically effective amount of an opioid analgesic or a salt thereof, coated with a controlled-release coating or in a controlled-release matrix, wherein the dissolution rate in-vitro of the dosage form, when measur ...


8
Richard Sackler, Robert Kaiko, Benjamin Oshlack, Richard Sackler, Robert Kaiko, Benjamin Oshlack: Opioid formulations having extended controlled release. Euroceltique, Euroceltique, CHEN WENQING, June 7, 1995: CN94107699

This invention relates to a solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the ...


9